1338 related articles for article (PubMed ID: 11295590)
1. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials.
Lieberman R
Urology; 2001 Apr; 57(4 Suppl 1):224-9. PubMed ID: 11295633
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of prostate cancer: current status and future directions.
Lieberman R
Cancer Metastasis Rev; 2002; 21(3-4):297-309. PubMed ID: 12549768
[TBL] [Abstract][Full Text] [Related]
4. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio.
Parnes HL; House MG; Kagan J; Kausal DJ; Lieberman R
J Urol; 2004 Feb; 171(2 Pt 2):S68-74; discussion S75. PubMed ID: 14713758
[TBL] [Abstract][Full Text] [Related]
6. Design considerations for efficient prostate cancer chemoprevention trials.
Lee JJ; Lieberman R; Sloan JA; Piantadosi S; Lippman SM
Urology; 2001 Apr; 57(4 Suppl 1):205-12. PubMed ID: 11295629
[TBL] [Abstract][Full Text] [Related]
7. Evolving strategies for prostate cancer chemoprevention trials.
Lieberman R
World J Urol; 2003 May; 21(1):3-8. PubMed ID: 12682772
[TBL] [Abstract][Full Text] [Related]
8. The NCI All Ireland Cancer Conference.
Johnston PG; Daly PA; Liu E
Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
[TBL] [Abstract][Full Text] [Related]
9. Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer.
Lieberman R
Am J Ther; 2004; 11(6):501-6. PubMed ID: 15543092
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents.
Nelson WG; Wilding G
Urology; 2001 Apr; 57(4 Suppl 1):56-63. PubMed ID: 11295596
[TBL] [Abstract][Full Text] [Related]
11. Chemoprevention of prostate cancer.
Kucuk O
Cancer Metastasis Rev; 2002; 21(2):111-24. PubMed ID: 12465750
[TBL] [Abstract][Full Text] [Related]
12. Delivering prostate cancer prevention messages to the public: how the National Cancer Institute (NCI) effectively spread the word about the Prostate Cancer Prevention Trial (PCPT) results.
Croker KS; Ryan A; Morzenti T; Cave L; Maze-Gallman T; Ford L
Urol Oncol; 2004; 22(4):369-76. PubMed ID: 15283899
[TBL] [Abstract][Full Text] [Related]
13. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
[TBL] [Abstract][Full Text] [Related]
14. Introductory remarks: development of chemopreventive agents for prostate cancer.
Kelloff GJ; Boone CW; Malone WF; Steele VE; Doody LA
J Cell Biochem Suppl; 1992; 16H():1-8. PubMed ID: 1289663
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development.
Lieberman R
Urology; 2001 Aug; 58(2 Suppl 1):83-90. PubMed ID: 11502457
[TBL] [Abstract][Full Text] [Related]
16. Can we prevent prostate cancer? Rationale and current status of prostate cancer chemoprevention.
Fujimoto N; Chang C; Nomura M; Matsumoto T
Urol Int; 2005; 74(4):289-97. PubMed ID: 15897691
[TBL] [Abstract][Full Text] [Related]
17. Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer.
Kelloff GJ; Lieberman R; Steele VE; Boone CW; Lubet RA; Kopelovich L; Malone WA; Crowell JA; Higley HR; Sigman CC
Urology; 2001 Apr; 57(4 Suppl 1):46-51. PubMed ID: 11295594
[TBL] [Abstract][Full Text] [Related]
18. Chemoprevention trials and surrogate end point biomarkers in the cervix.
Mitchell MF; Hittelman WK; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Wharton JT; Hong WK
Cancer; 1995 Nov; 76(10 Suppl):1956-77. PubMed ID: 8634987
[TBL] [Abstract][Full Text] [Related]
19. Reducing the "risk" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture.
Lippman SM; Lee JJ
Cancer Res; 2006 Mar; 66(6):2893-903. PubMed ID: 16540634
[TBL] [Abstract][Full Text] [Related]
20. Proceedings of the Indo-U.S. bilateral workshop on accelerating botanicals/biologics agent development research for cancer chemoprevention, treatment, and survival.
Kumar NB; Dhurandhar M; Aggarwal B; Anant S; Daniel K; Deng G; Djeu J; Dou J; Hawk E; Jayaram B; Jia L; Joshi R; Kararala M; Karunagaran D; Kucuk O; Kumar L; Malafa M; Samathanam GJ; Sarkar F; Siddiqi M; Singh RP; Srivastava A; White JD
Cancer Med; 2013 Feb; 2(1):108-15. PubMed ID: 24279005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]